Supplementary Material

Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia

Matthew Davis, Thomas O'Connell, Scott Johnson, Stephanie Cline*, Elizabeth Merikle, Ferenc Martenyi and Kit N. Simpson

Medicus Economics Milton, Massachusetts, United States, Takeda Pharmaceuticals USA Inc Ringgold standard institution - Global Outcomes Research, Takeda Parkway , Deerfield, Illinois 60015-5713, United States; Medical University of South Carolina Ringgold standard institution, Charleston, South Carolina, United States

A.



AD, Alzheimer's disease; MCI, mild cognitive impairment

B.



AD, Alzheimer's disease; MCI, mild cognitive impairment

1567-2050/18 $58.00+.00

C.

For a cohort of size:	100
For a 2-year delay in risk of MCI due to AD:	
Cases of MCI due to AD avoided:	4.01
Cases of AD dementia avoided:	4.00
Average delay in onset of AD (years):	1.47
Average increase in patient survival (years):	0.42
Average increase in time with normal cognition (years):	0.83
Average reduction of time in long-term care (years):	0.03

AD, Alzheimer's disease; MCI, mild cognitive impairment

Fig. (S1). Modeling the effects of a 2-year delay in risk of transitioning from normal cognition to MCI due to AD in a cohort of 100 normal cognition patients at age 65 years. A: Progression with and without a 2-year delay in the risk of transitioning from normal cognition to MCI due to AD; B: Transitions with and without a 2-year delay in the risk of transitioning from normal cognition to MCI due to AD; C: Epidemiology results for a 2-year delay in the risk of transitioning from normal cognition to MCI due to AD.